AbbVie Inc. Depreciation & Amortization Growth

Depreciation & Amortization Growth of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Depreciation & Amortization Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Depreciation & Amortization Growth for the quarter ending September 29, 2019 was 15.63% (a 17.34% increase compared to previous quarter)
  • Year-over-year quarterly Depreciation & Amortization Growth decreased by -20.98%
  • Annual Depreciation & Amortization Growth for 2018 was 17.59% (a -32.96% decrease from previous year)
  • Annual Depreciation & Amortization Growth for 2017 was 26.24% (a -37.85% decrease from previous year)
  • Annual Depreciation & Amortization Growth for 2016 was 42.22% (a 563.84% increase from previous year)
  • Twelve month Depreciation & Amortization Growth ending September 29, 2019 was 15.25% (a 1.4% increase compared to previous quarter)
  • Twelve month trailing Depreciation & Amortization Growth decreased by -13.3% year-over-year
Trailing Depreciation & Amortization Growth for the last four month:
29 Sep '19 29 Jun '19 30 Mar '19 30 Dec '18
15.25% 15.04% 15.97% 17.59%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Depreciation & Amortization Growth of AbbVie Inc.

Most recent Depreciation & Amortization Growthof ABBV including historical data for past 10 years.

Interactive Chart of Depreciation & Amortization Growth of AbbVie Inc.

AbbVie Inc. Depreciation & Amortization Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 15.63% 13.32% 13.03%
2018 19.78% 14.78% 16.89% 18.98% 17.59%
2017 12.5% 24.67% 31.14% 39.55% 26.24%
2016 25.67% 33.92% 52.11% 69.62% 42.22%
2015 35.23% 18.23% -5.94% -20.6% 6.36%
2014 -3.5% -17.95% -14.41% -12.33% -12.37%
2013 -35.28% 3.08% -20.0% -28.84% -22.0%
2012 -4.89% -27.99% -7.12% 1.44% -9.59%
2011 -72.57% -54.8% 7.43%
2010 69.75%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.